CRISPR Therapeutics (NASDAQ:CRSP) Issues Earnings Results

Posted by Stanley Muller on Aug 3rd, 2026

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.94) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.26, FiscalAI reports. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The firm had revenue of $10.18 million during the quarter, compared to analysts’ expectations of $7.45 million.

CRISPR Therapeutics Stock Performance

Shares of CRSP traded up $1.58 during trading hours on Monday, hitting $49.57. The company had a trading volume of 1,397,013 shares, compared to its average volume of 1,809,020. The firm has a market cap of $4.78 billion, a price-to-earnings ratio of -7.97 and a beta of 1.74. The business has a fifty day moving average of $52.52 and a 200-day moving average of $52.40. CRISPR Therapeutics has a 12 month low of $44.12 and a 12 month high of $78.48. The company has a quick ratio of 17.96, a current ratio of 17.97 and a debt-to-equity ratio of 0.32.

Insider Activity at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,786 shares of CRISPR Therapeutics stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $55.62, for a total transaction of $210,577.32. Following the completion of the sale, the insider owned 19,357 shares of the company’s stock, valued at approximately $1,076,636.34. The trade was a 16.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds have recently bought and sold shares of CRSP. Prudential Financial Inc. acquired a new position in shares of CRISPR Therapeutics in the second quarter valued at approximately $237,000. Moneta Group Investment Advisors LLC acquired a new stake in CRISPR Therapeutics during the 3rd quarter worth approximately $236,000. Meeder Advisory Services Inc. boosted its stake in CRISPR Therapeutics by 6.6% in the 4th quarter. Meeder Advisory Services Inc. now owns 4,392 shares of the company’s stock valued at $230,000 after purchasing an additional 270 shares during the period. Twinbeech Capital LP bought a new stake in CRISPR Therapeutics in the 4th quarter valued at $214,000. Finally, Brooklyn Investment Group bought a new stake in CRISPR Therapeutics in the 4th quarter valued at $208,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on CRSP shares. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, July 8th. UBS Group set a $80.00 price target on CRISPR Therapeutics in a report on Friday, June 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Friday, July 17th. Sanford C. Bernstein upped their price objective on CRISPR Therapeutics from $50.00 to $56.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $67.78.

Check Out Our Latest Report on CRSP

CRISPR Therapeutics Company Profile

(Get Free Report)

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.